Peptides Studied for Immune Support

Immune support is an area where one peptide stands well above the rest in terms of clinical validation. Thymosin Alpha-1 (thymalfasin) is approved in over 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant. It has been studied in more than 11,000 subjects across decades of clinical use.

Despite this international track record, Thymosin Alpha-1 is not FDA-approved in the United States. Its story illustrates how regulatory status and clinical evidence don't always align — a peptide can have strong human data and broad international approval while remaining unavailable through conventional US channels.

Other peptides in our database have tangential immune research — Selank has immunomodulatory properties, and KPV has anti-inflammatory effects — but none approach Thymosin Alpha-1's depth of clinical evidence for immune function specifically.